[Wall Street Journal] ‘Unsustainable for Our Country’: Express Scripts Calls Out Pricey Meds

By Ed Silverman April 8, 2014   Each year, Express Scripts, the largest pharmacy benefits manager in the U.S., ceremoniously releases a spending forecast for prescription […]

Read more

[Bloomberg] Gilead’s $84,000 Treatment Questioned by U.S. Lawmakers

By Drew Armstrong Mar. 21, 2014   Gilead Sciences Inc. (GILD) is being asked by U.S. House Democrats to explain how the company set its $84,000 price […]

Read more

[New York Times] How Much Should Hepatitis C Treatment Cost?

Editorial Board March 16   A new pill to treat hepatitis C raises difficult questions about fair pricing, not only in the United States and other affluent nations […]

Read more

[Associated Press] Medical Groups Question Price Of New Hep C Drug

By Matthew Perrone March 11, 2014   An innovative hepatitis C drug that was only recently hailed as a breakthrough treatment is facing skepticism from some […]

Read more